Overview Sorafenib and RAD001 Renal Cell Carcinoma Status: Completed Trial end date: 2014-03-01 Target enrollment: Participant gender: Summary The objective of the phase I part of the study is to determine the maximum tolerated dose and dose limiting toxicities of the combination of RAD001 and sorafenib in patients with untreated metastatic kidney cancer. Phase: Phase 1 Details Lead Sponsor: University of California, San FranciscoCollaborator: NovartisTreatments: EverolimusNiacinamideSirolimusSorafenib